Biogen nabs speedy FDA review for controversial Alzheimer’s drug

[cafead]

via Biogen’s aducanumab is inching closer to an FDA decision. The Big Biotech, along with partner Eisai, announced on Friday that the FDA accepted its regulatory submission for aducanumab, its once-failed Alzheimer’s drug—with priority review to boot.

article source